Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) is set to announce topline results from its Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist for the treatment of metabolic-dysfunction associated steatohepatitis (MASH), on September 19, 2024. The company, focused on developing therapies for liver and viral diseases, will release the results before market open and host a conference call and webcast at 8:30am ET/5:30am PT to discuss the findings.

Investors and interested parties can access the live webcast with slides on the Aligos website's Presentation & Events page. A replay of the webcast will be available for 90 days following the live presentation.

Positive

• Upcoming release of Phase 2a clinical trial results for ALG-055009
• Potential advancement in treatment for metabolic-dysfunction associated steatohepatitis (MASH)
• Transparency through investor conference call and webcast

Negative

• None.

Insights

Medical Research Analyst

The upcoming announcement of topline results from Aligos Therapeutics' Phase 2a HERALD study for ALG-055009 is a significant milestone in the development of treatments for MASH (metabolic dysfunction-associated steatohepatitis). As a THR-β agonist, ALG-055009 represents a novel approach to addressing this complex liver disease.

The results will provide important insights into the efficacy and safety profile of ALG-055009, potentially positioning Aligos as a key player in the MASH treatment landscape. Investors should pay close attention to key endpoints such as liver fat reduction, fibrosis improvement and safety data. Positive results could significantly boost Aligos' market position and attract potential partnerships, while negative outcomes might necessitate a reevaluation of the company's pipeline strategy.

Financial Analyst

Aligos Therapeutics' imminent release of Phase 2a results for ALG-055009 could be a pivotal moment for the company's valuation. The MASH market is projected to reach $21.5 billion by 2025, presenting a substantial opportunity. Positive results could lead to a significant stock price movement, potentially attracting institutional investors and improving the company's financial position for future trials.

However, investors should be cautious. Biotech stocks are notoriously volatile around clinical trial results. The current market cap of Aligos ($54.7 million as of last close) suggests that positive results are not fully priced in, leaving room for upside but also indicating skepticism. A thorough analysis of the data and its implications for future phases will be important for assessing the long-term value proposition of Aligos.

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT.

Conference Call & Webcast Details

The company will host a conference call and webcast with a slide presentation tomorrow at 8:30am ET/5:30am PT. To access the live webcast with slides, please visit the Presentation & Events page on the Aligos website at www.aligos.com. Please register ten minutes prior to its start. Following the live webcast, a replay will be available on the company’s website for 90 days.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.  

Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inzioevoke.com

FAQ

What are the topline results of Aligos Therapeutics' Phase 2a HERALD study for ALGS?

The topline results of Aligos Therapeutics' Phase 2a HERALD study for ALG-055009 in MASH patients will be announced on September 19, 2024, before the market opens. The company will host a conference call and webcast at 8:30am ET/5:30am PT to discuss the findings.

What is ALG-055009 and what condition does it target for Aligos Therapeutics (ALGS)?

ALG-055009 is a thyroid hormone receptor beta (THR-β) agonist developed by Aligos Therapeutics. It targets metabolic-dysfunction associated steatohepatitis (MASH), a liver disease associated with metabolic disorders.

When and where can investors access the webcast for Aligos Therapeutics' (ALGS) HERALD study results?

Investors can access the live webcast with slides on September 19, 2024, at 8:30am ET/5:30am PT on the Presentation & Events page of the Aligos website (www.aligos.com). A replay will be available for 90 days after the live presentation.

What phase of clinical trials is Aligos Therapeutics' (ALGS) ALG-055009 currently in?

ALG-055009 is currently in Phase 2a clinical trials, as evidenced by the HERALD study results announcement scheduled for September 19, 2024.